Computer-aided drug design for amp-activated protein kinase activators

Current Computer-Aided Drug Design

Volumn 7, Issue 3, 2011, Pages 214-227

  Wang, Zhanli ^a   Huo, Jianxin ^a   Sun, Lidan ^b   Wang, Yongfu ^a   Jin, Hongwei ^b   Yu, Hui ^c   Zhang, Liangren ^b   Zhou, Lishe ^a  

^a BAOTOU MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

Activator; Amp activated protein kinase; Fragment based drug design; Ligand based drug design; Structural analysis; Structure based drug design

Indexed keywords

COMPUTER AIDED ANALYSIS; DISEASES; ENZYME ACTIVITY; STRUCTURAL ANALYSIS;

ACTIVATOR; AMP-ACTIVATED PROTEIN KINASE; COMPUTER AIDED DRUG DESIGN; DESIGN APPROACHES; DRUG DESIGN; FRAGMENT-BASED DRUG DESIGN; LIGAND-BASED DRUG DESIGN; STRUCTURE BASED DRUG DESIGNS; THERAPEUTIC TARGETS;

LIGANDS;

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENYLATE KINASE; BERBERINE; CORDYCEPIN; CURCUMIN; D 942; EPIGALLOCATECHIN GALLATE; FATTY ACID; GINSENOSIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; ISOGINKGETIN; METFORMIN; METHYLEUGENOL; NUCLEOTIDE DERIVATIVE; PIOGLITAZONE; PT 1; QUERCETIN; ROSIGLITAZONE; THEAFLAVIN; TRITERPENOID; TROGLITAZONE; UNCLASSIFIED DRUG; XYLOSE;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; GLUCOSE TRANSPORT; LIPID METABOLISM; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIGNAL TRANSDUCTION;

EID: 79961052326     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/157340911796504323     Document Type: Article

References (131)

1. Carlson, C.A.; Kim, K.H. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J. Biol. Chem., 1973, 248, 378-380.
2. Beg, Z.H.; Allmann, D.W.; Gibson, D.M. Modulation of 3- hydroxy-3- methylglutaryl coenzyme A reductase activity with cAMP and with protein fractions of rat liver cytosol. Biochem. Biophys. Res. Commun., 1973, 54, 1362-1369.
3. Munday, M.R.; Campbell, D.G.; Carling, D.; Hardie, D.G. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem., 1988, 175, 331-338.
4. Fogarty, S.; Hardie, D.G. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim. Biophys. Acta., 2010, 1804, 581-591.
5. Hardie, D.G.; Hawley, S.A. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays, 2001, 23, 1112-1119.
6. Hardie, D.G. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett., 2008, 582, 81-89.
7. Hardie, D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev., Mol. Cell Biol., 2007, 8, 774-785.
8. Dzamko, N.L.; Steinberg, G.R. AMPK-dependent hormonal regulation of whole body energy metabolism. Acta. Physiol., 2009, 196, 115-127.
9. Yu, L.F.; Qiu, B.Y.; Nan, F.J.; Li, J. AMPK activators as novel therapeutics for type 2 diabetes. Curr. Top. Med. Chem., 2010, 10, 397-410.
10. Li, C.; Keaney, J.F. Jr. AMP-activated protein kinase: a stressresponsive kinase with implications for cardiovascular disease. Curr. Opin. Pharmacol., 2010, 10, 111-115.
11. Motoshima, H.; Goldstein, B.J.; Igata, M.; Araki, E. AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol., 2006, 574, 63-71.
12. Luo, Z.; Zang, M.; Guo, W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol., 2010, 6, 457-470.
13. Hardie, D.G. AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 185 210.
14. Hawley, S.A.; Davison, M.; Woods, A.; Davies, S.P.; Beri, R.K.; Carling, D.; Hardie, D.G. Characterization of the AMP-activated protein kinase kinase from rat liver, and identification of threonine- 172 as the major site at which it phosphorylates and activates AMP-activated protein kinase. J. Biol. Chem., 1996, 271, 27879-27887.
15. Suter, M.; Riek, U.; Tuerk, R.; Schlattner, U.; Wallimann, T.; Neumann, D. Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP activated protein kinase. J. Biol. Chem., 2006, 281, 32207-32216.
16. Crute, B.E.; Seefeld, K.; Gamble, J.; Kemp, B.E.; Witters, L.A. Functional domains of the alpha1 catalytic subunit of the AMPactivated protein kinase. J. Biol. Chem., 1998, 273, 35347-35354.
17. Pang, T.; Xiong, B.; Li, J.Y.; Qiu, B.Y.; Jin, G.Z.; Shen, J.K.; Li, J. Conserved alpha-helix acts as autoinhibitory sequence in AMPactivated protein kinase alpha subunits. J. Biol. Chem., 2007, 282, 495-506.
18. Goransson, O.; McBride, A.; Hawley, S.A.; Ross, F.A.; Shpiro, N.; Foretz, M.; Viollet, B.; Hardie, D.G.; Sakamoto, K. Mechanism of action of A-769662, a valuable tool for activation of AMPactivated protein kinase. J. Biol. Chem., 2007, 282, 32549-32560.
19. Hudson, E.R.; Pan, D.A.; James, J.; Lucocq, J.M.; Hawley, S.A.; Green, K.A.; Baba, O.; Terashima, T.; Hardie, D.G. A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr. Biol., 2003, 13, 861-866.
20. Sanders, M.J.; Ali, Z.S.; Hegarty, B.D.; Heath, R.; Snowden, M.A.; Carling, D. Defining the mechanism of activation of AMPactivated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem., 2007, 282, 32539-32548.
21. Scott, J.W.; Hawley, S.A.; Green, K.A.; Anis, M.; Stewart, G.; Scullion, G.A.; Norman, D.G.; Hardie, D.G. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J. Clin. Invest., 2004, 113, 274-284.
22. Wong, K.A.; Lodish, H.F. A revised model for AMP-activated protein kinase structure: the alpha-subunit binds to both the betaand gamma-subunits although there is no direct binding between the beta- and gamma-subunits. J. Biol. Chem., 2006, 281, 36434-36442.
23. Carling, D. AMP-activated protein kinase: balancing the scales. Biochimie, 2005, 87, 87-91.
24. Carling, D. AMPK. Curr. Biol., 2004, 14, R220.
25. Townley, R.; Shapiro, L. Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. Science, 2007, 315, 1726-1729.
26. Xiao, B.; Heath, R.; Saiu, P.; Leiper, F.C.; Leone, P.; Jing, C.; Walker, P.A.; Haire, L.; Eccleston, J.F.; Davis, C.T.; Martin, S.R.; Carling, D.; Gamblin, S.J. Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature, 2007, 449, 496-500.
27. Amodeo, G.A.; Rudolph, M.J.; Tong, L. Crystal structure of the heterotrimer core of Saccharomyces cerevisiae AMPK homologue SNF1. Nature, 2007, 449, 492-495.
28. Chen, L.; Jiao, Z.H.; Zheng, L.S.; Zhang, Y.Y.; Xie, S.T.; Wang, Z.X.; Wu, J.W. Structural insight into the autoinhibition mechanism of AMP-activated protein kinase. Nature, 2009, 459, 1146-1149.
29. Sanders, M.J.; Grondin, P.O.; Hegarty, B.D.; Snowden, M.A.; Carling, D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem. J., 2007, 403, 139-148.
30. Davies, S.P.; Helps, N.R.; Cohen, P.T.W.; Hardie, D.G. 5'-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C and native bovine protein phosphatase-2AC. FEBS Lett., 1995, 377, 421-425.
31. McBride, A.; Hardie, D.G. AMP-activated protein kinase--a sensor of glycogen as well as AMP and ATP? Acta. Physiol. (Oxf)., 2009, 196, 99-113.
32. Shaw, R.J.; Kosmatka, M.; Bardeesy, N.; Hurley, R.L.; Witters, L.A.; DePinho, R.A.; Cantley, L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 3329 3335.
33. Alessi, D.R.; Sakamoto, K.; Bayascas, J.R. Lkb1-dependent signaling pathways. Annu. Rev. Biochem., 2006, 75, 137 163.
34. Hawley, S.A.; Boudeau, J.; Reid, J.L.; Mustard, K.J.; Udd, L.; Makela, T.P.; Alessi, D.R.; Hardie, D.G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol., 2003, 2, 28.
35. Hawley, S.A.; Pan, D.A.; Mustard, K.J.; Ross, L.; Bain, J.; Edelman, A.M.; Frenguelli, B.G.; Hardie, D.G. Calmodulindependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell. Metab., 2005, 2, 9-19.
36. Woods, A.; Dickerson, K.; Heath, R.; Hong, S.P.; Momcilovic, M.; Johnstone, S.R.; Carlson, M.; Carling, D. Ca2+/calmodulindependent protein kinase kinase-beta acts upstream of AMPactivated protein kinase in mammalian cells. Cell. Metab., 2005, 2, 21-33.
37. Carling, D.; Sanders, M.J.; Woods, A. The regulation of AMPactivated protein kinase by upstream kinases. Int. J. Obes. (Lond)., 2008, 32, S55-S59.
38. Momcilovic, M.; Hong, S.P.; Carlson, M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMPactivated protein kinase in vitro. J. Biol. Chem., 2006, 281, 25336-25343.
39. McGee, S.L.; Mustard, K.J.; Hardie, D.G.; Baar, K. Normal hypertrophy accompanied by phosphoryation and activation of AMP-activated protein kinase alpha1 following overload in LKB1 knockout mice. J. Physiol., 2008, 586, 1731-1741.
40. Kurth-Kraczek, E.J.; Hirshman, M.F.; Goodyear, L.J.; Winder, W.W. 5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes, 1999, 48, 1667-1671.
41. Barnes, K.; Ingram, J.C.; Porras, O.H.; Barros, L.F.; Hudson, E.R.; Fryer, L.G.; Foufelle, F.; Carling, D.; Hardie, D.G.; Baldwin, S.A. Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J. Cell. Sci., 2002, 115, 2433-2442.
42. Zheng, D.; MacLean, P.S.; Pohnert, S.C.; Knight, J.B.; Olson, A.L.; Winder, W.W.; Dohm, G.L. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J. Appl. Physiol., 2001, 91, 1073-1083.
43. Saha, A.K.; Ruderman, N.B. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol. Cell. Biochem., 2003, 253, 65-70.
44. Hardie, D.G.; Pan, D.A. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans., 2002, 30, 1064-1070.
45. Ching, Y.P.; Davies, S.P.; Hardie, D.G. Analysis of the specificity of the AMP-activated protein kinase by site-directed mutagenesis of bacterially expressed 3-hydroxy 3-methylglutaryl-CoA reductase, using a single primer variant of the uniquesiteelimination method. Eur. J. Biochem., 1996, 237, 800-808.
46. Pallottini, V.; Montanari, L.; Cavallini, G.; Bergamini, E.; Gori, Z.; Trentalance, A. Mechanisms underlying the impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in aged rat liver. Mech. Ageing Dev., 2004, 125, 633-639.
47. Rosner, M.; Hanneder, M.; Siegel, N.; Valli, A.; Hengstschläger, M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat. Res., 2008, 658, 234-246.
48. Davies, J.K.; Wells, D.J.; Liu, K.; Whitrow, H.R.; Daniel, T.D.; Grignani, R.; Lygate, C.A.; Schneider, J.E.; Noël, G.; Watkins, H.; Carling, D. Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H1942-H1951.
49. Cantó, C.; Auwerx, J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell. Mol. Life Sci., 2010, 67, 3407-3423.
50. Steinberg, G.R.; Kemp, B.E. AMPK in health and disease. Physiol. Rev., 2009, 89, 1025-1078.
51. Zadra, G.; Priolo, C.; Patnaik, A.; Loda, M. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin. Cancer Res., 2010, 16, 3322-3328.
52. McGee, S.L.; Hargreaves, M. AMPK-mediated regulation of transcription in skeletal muscle. Clin. Sci. (Lond)., 2010, 118, 507-518.
53. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 2002, 346, 393-403.
54. Bailey, C.J.; Turner, R.C. Metformin. N. Engl. J. Med., 1996, 334, 574-579.
55. Musi, N.; Hirshman, M.F.; Nygren, J.; Svanfeldt, M.; Bavenholm, P.; Rooyackers, O.; Zhou, G.; Williamson, J.M.; Ljunqvist, O.; Efendic, S.; Moller, D.E.; Thorell, A.; Goodyear, L.J. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 2002, 51, 2074-2081.
56. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J.; Moller, D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 2001, 108, 1167-1174.
57. Hawley, S.A.; Gadalla, A.E.; Olsen, G.S.; Hardie, D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes, 2002, 51, 2420-2425.
58. Zhang, L.; He, H.; Balschi, J.A. Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H457-H466.
59. Sakamoto, K.; Goransson, O.; Hardie, D.G.; Alessi, D.R. Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR. Am. J. Physiol. Endocrinol. Metab., 2004, 287, E310-E317.
60. Foretz, M.; Hébrard, S.; Leclerc, J.; Zarrinpashneh, E.; Soty, M.; Mithieux, G.; Sakamoto, K.; Andreelli, F.; Viollet, B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest., 2010, 120, 2355-2369.
61. Shu, Y.; Sheardown, S.A.; Brown, C.; Owen, R.P.; Zhang, S.; Castro, R.A.; Ianculescu, A.G.; Yue, L.; Lo, J.C.; Burchard, E.G.; Brett, C.M.; Giacomini, K.M. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest., 2007, 117, 1422-1431.
62. Schimmack, G.; Defronzo, R.A.; Musi, N. AMP-activated protein kinase: Role in metabolism and therapeutic implications. Diabetes Obes. Metab., 2006, 8, 591-602.
63. Lebrasseur, N.K.; Kelly, M.; Tsao, T.S.; Farmer, S.R.; Saha, A.K.; Ruderman, N.B.; Tomas, E. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab. 2006, 291, E175-E181.
64. Brunmair, B.; Staniek, K.; Gras, F.; Scharf, N.; Althaym, A.; Clara, R.; Roden, M.; Gnaiger, E.; Nohl, H.; Waldhausl, W.; Furnsinn, C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes, 2004, 53, 1052-1059.
65. Fryer, L.G.; Parbu-Patel, A.; Carling, D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem., 2002, 277, 25226-25232.
66. Merrill, G.F.; Kurth, E.J.; Hardie, D.G.; Winder, W.W. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am. J. Physiol., 1997, 273, E1107-E1112.
67. Zhou, G.; Sebhat, I.K.; Zhang, B.B. AMPK activators--potential therapeutics for metabolic and other diseases. Acta. Physiol. (Oxf)., 2009, 196, 175-190.
68. Charton, J.; Girault-Mizzi, S.; Debreu-Fontaine, M.A.; Foufelle, F.; Hainault, I.; Bizot-Espiard, J.G.; Caignard, D.H.; Sergheraert, C. Synthesis and biological evaluation of benzimidazole derivatives as potent AMP-activated protein kinase activators. Bioorg. Med. Chem., 2006, 14, 4490-4518.
69. Moinet, G.; Marais, D.; Hallakou-Bozec, S.; Charon, C. Use of AMPK-activating imidazole derivatives, preparation process and pharmaceutical compositions comprising them. Patent no. WO/2008/006432. January 17, 2008.
70. Rault, S.; Lancelot, J.C.; Kopp, M.; Caignard, D.H.; Pfeiffer, B.; Renard, P.; Bizot Espiard, J.G. New imidazopyridine derivatives are AMP activated protein kinase activators, useful in the treatment of diabetes, hypercholesterolemia, hyperlipidemia, obesity, and diabetic complications in cardiovascular system. Patent no. FR2846656. May 07, 2007.
71. Wong, Y.Y.; Moon, A.; Duffin, R.; Barthet-Barateig, A.; Meijer, H.A.; Clemens, M.J.; de Moor, C.H. Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J. Biol. Chem., 2010, 285, 2610-21.
72. Guo, P.; Kai, Q.; Gao, J.; Lian, Z.Q.; Wu, C.M.; Wu, C.A.; Zhu, H.B. Cordycepin prevents hyperlipidemia in hamsters fed a highfat diet via activation of AMP-activated protein kinase. J. Pharmacol. Sci., 2010, 113, 395-403.
73. Wang, Z.; Wang, X.; Qu, K.; Zhu, P.; Guo, N.; Zhang, R.; Abliz, Z.; Yu, H.; Zhu, H. Binding of cordycepin monophosphate to AMP-activated protein kinase and its effect on AMP-activated protein kinase activation. Chem. Biol. Drug Des., 2010, 76, 340-344.
74. Kosaka, T.; Okuyama, R.; Sun, W.; Ogata, T.; Harada, J.; Araki, K.; Izumi, M.; Yoshida, T.; Okuno, A.; Fujiwara, T.; Ohsumi, J.; Ichikawa, K. Identification of molecular target of AMP-activated protein kinase activator by affinity purification and mass spectrometry. Anal. Chem., 2005, 77, 2050-2055.
75. Gruzman, A.; Shamni, O.; Ben Yakir, M.; Sandovski, D.; Elgart, A.; Alpert, E.; Cohen, G.; Hoffman, A.; Katzhendler, Y.; Cerasi, E.; Sasson, S. Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase alpha. J. Med. Chem., 2008, 51, 8096-8108.
76. Gruzman, A.; Babai, G.; Sasson, S. Adenosine monophosphateactivated protein kinase (AMPK) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations. Rev. Diabet. Stud., 2009, 6, 13-36.
77. Hwang, J.T.; Ha, J.; Park, I.J.; Lee, S.K.; Baik, H.W.; Kim, Y.M.; Park, O.J. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett., 2007, 247, 115-121.
78. Collins, Q.F.; Liu, H.Y.; Pi, J.; Liu, Z.; Quon, M.J.; Cao, W. Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. J. Biol. Chem., 2007, 282, 30143-30149.
79. Breen, D.M.; Sanli, T.; Giacca, A.; Tsiani, E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem. Biophys. Res. Commun., 2008, 374, 117-122.
80. Ahn, J.; Lee, H.; Kim, S.; Park, J.; Ha, T. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem. Biophys. Res. Commun., 2008, 373, 545-549.
81. Hwang, J.T.; Kim, S.H.; Lee, M.S.; Kim, S.H.; Yang, H.J.; Kim, M.J.; Kim, H.S.; Ha, J.; Kim, M.S.; Kwon, D.Y. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem. Biophys. Res. Commun., 2007, 364, 1002-1008.
82. Pan, W.; Yang, H.; Cao, C.; Song, X.; Wallin, B.; Kivlin, R.; Lu, S.; Hu, G.; Di, W.; Wan, Y. AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells. Oncol. Rep., 2008, 20, 1553-1559.
83. Liang, K.W.; Yin, S.C.; Ting, C.T.; Lin, S.J.; Hsueh, C.M.; Chen, C.Y.; Hsu, S.L. Berberine inhibits platelet-derived growth factorinduced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. Eur. J. Pharmacol., 2008, 590, 343-354.
84. Lin, C.L.; Huang, H.C.; Lin, J.K. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J. Lipid Res., 2007, 48, 2334-2343.
85. Liu, G.; Grifman, M.; Macdonald, J.; Moller, P.; Wong-Staal, F.; Li, Q.X. Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase. J. Endocrinol., 2007, 194, 569-578.
86. Tan, M.J.; Ye, J.M.; Turner, N.; Hohnen-Behrens, C.; Ke, C.Q.; Tang, C.P.; Chen, T.; Weiss, H.C.; Gesing, E.R.; Rowland, A.; James, D.E.; Ye, Y. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem. Biol., 2008, 15, 263-273.
87. Cool, B.; Zinker, B.; Chiou, W.; Kifle, L.; Cao, N.; Perham, M.; Dickinson, R.; Adler, A.; Gagne, G.; Iyengar, R.; Zhao, G.; Marsh, K.; Kym, P.; Jung, P.; Camp, H.S.; Frevert, E. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab., 2006, 3, 403-416.
88. Pang, T.; Zhang, Z.S.; Gu, M.; Qiu, B.Y.; Yu, L.F.; Cao, P.R.; Shao, W.; Su, M.B.; Li, J.Y.; Nan, F.J.; Li, J. Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J. Biol. Chem., 2008, 283, 16051-16060.
89. Dias, R.; de Azevedo, W.F. Jr. Molecular docking algorithms. Curr. Drug Targets, 2008, 9, 1040-1047.
90. Huang, S.Y.; Zou, X. Advances and challenges in protein-ligand docking. Int. J. Mol. Sci., 2010, 11, 3016-3034.
91. Polekhina, G.; Gupta, A.; Michell, B.J.; van Denderen, B.; Murthy, S.; Feil, S.C.; Jennings, I.G.; Campbell, D.J.; Witters, L.A.; Parker, M.W.; Kemp, B.E.; Stapleton, D. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr. Biol., 2003, 13, 867-871.
92. Polekhina, G.; Gupta, A.; van Denderen, B.J.; Feil, S.C.; Kemp, B.E.; Stapleton, D.; Parker, M.W. Structural basis for glycogen recognition by AMP-activated protein kinase. Structure, 2005, 13, 1453-1462.
93. De Azevedo, W.F. Jr. Structure-based virtual screening. Curr. Drug Targets, 2010, 11, 261-263.
94. Goodsell, D.S.; Morris, G.M.; Olson, A.J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recog., 1996, 9, 1-5.
95. Zsoldos, Z.; Reid, D.; Simon, A.; Sadjad, B.S.; Johnson, A.P. eHiTS: an innovative approach to the docking and scoring function problems. Curr. Protein Pept. Sci., 2006, 7, 421-435.
96. Gastreich, M.; Lilienthal, M.; Briem, H.; Claussen, H. Ultrafast de novo docking combining pharmacophores and combinatorics. J. Comput. Aided Mol. Des., 2006, 20, 717-734.
97. Fernandez-Recio, J.; Totrov, M.; Abagyan, R. ICM-DISCO docking by global energy optimization with fully flexible sidechains. Proteins, 2003, 52,113-117.
98. Schultz-Gasch, T.; Stahl, M. Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J. Mol. Model, 2003, 9, 47-57.
99. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 2006, 49, 6177-6196.
100. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray C.W.; Taylor, R.D. Improved protein-ligand docking using GOLD. Proteins, 2003, 52, 609-623.
101. Venkatachalam, C.M.; Jiang, X.; Oldfield, T.; Waldmanm M. Lig and Fit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model, 2003, 21, 289-307.
102. Erion, M.D.; Dang, Q.; Reddy, M.R.; Kasibhatla, S.R.; Huang, J.; Lipscomb, W.N.; van Poelje, P.D. Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity. J. Am. Chem. Soc., 2007, 129, 15480-15490.
103. Vincent, M.F.; Marangos, P.J.; Gruber, H.E.; Van den Berghe, G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes, 1991, 40, 1259-1266.
104. Longnus, S.L.; Wambolt, R.B.; Parsons, H.L.; Brownsey, R.W.; Allard, M.F. 5-Aminoimidazole-4-carboxamide 1-beta-Dribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2003, 284, R936-R944.
105. Vincent, M.F.; Bontemps, F.; Van den Berghe, G. Inhibition of glycolysis by 5-amino-4-imidazolecarboxamide riboside in isolated rat hepatocytes. Biochem. J., 1992, 281, 267-272.
106. Huang, H.J.; Chen, C.Y.; Chen, H.Y.; Tsai, F.J.; Chen, C.Y.C. Computational screening and QSAR analysis for design of AMPactivated protein kinase agonist. J. Taiwan Inst. Chem. Eng., 2010, 41, 352-359.
107. Acharya, C.; Coop, A.; Polli, J.E.; Mackerell, A.D. Jr. Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr. Comput. Aided Drug Des., 2011, 7, 10-22.
108. Favia, A.D. Theoretical and computational approaches to ligandbased drug discovery. Front. Biosci., 2011, 16, 1276-1290.
109. Funatsu, K.; Miyao, T.; Arakawa, M. Systematic generation of chemical structures for rational drug design based on QSAR models. Curr. Comput. Aided Drug Des., 2011, 7, 1-9.
110. Zhao, G.; Iyengar, R.R.; Judd, A.S.; Cool, B.; Chiou, W.; Kifle, L.; Frevert, E.; Sham, H.; Kym, P.R. Discovery and SAR development of thienopyridones: a class of small molecule AMPK activators. Bioorg. Med. Chem. Lett., 2007, 17, 3254-3257.
111. Graziani, Y.; Chayoth, R.; Karny, N.; Feldman, B.; Levy, J. Regulation of protein kinases activity by quercetin in Ehrlich ascites tumor cells. Biochim. Biophys. Acta., 1982, 714, 415-421.
112. Chang, C.J.; Geahlen, R.L. Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J. Nat. Prod., 1992, 55, 1529-1560.
113. Nikolovska-Coleska, Z.; Suturkova, L.; Dorevski, K.; Krbavcic, A.; Solmajer, T. Quantitative structure-activity relationship of flavonoid inhibitors of p56(lck) protein tyrosine kinase: A classical/quantum chemical approach. Quant. Struct. Act. Relat., 1998, 17, 7-13.
114. Oblak, M.; Randic, M.; Solmajer, T. Quantitative structure-activity relationship of flavonoid analogues. 3. Inhibition of p56(lck) protein tyrosine kinase. J. Chem. Inf. Comput. Sci., 2000, 40, 994-1001.
115. Stefanic-Petek, A.; Krbavcic, A.; Solmajer, T. QSAR of flavonoids: 4. Differential inhibition of aldose reductase and p56(lck) protein tyrosine kinase. Croat. Chem. Act., 2000, 5, 517-529.
116. Thakur, A.; Vishwakarma, S.; Thakur, M. QSAR study of flavonoid derivatives as p56lck tyrosinkinase inhibitors. Bioorg. Med. Chem., 2004, 12, 1209-1214.
117. Deeb, O.; Clare, B.W. QSAR of aromatic substances: protein tyrosine kinase inhibitory activity of flavonoid analogues. Chem. Biol. Drug Des., 2007, 70, 437-449.
118. Gao, Q.; Yang, L.; Zhu, Y. Pharmacophore based drug design approach as a practical process in drug discovery. Curr. Comput. Aided Drug Des., 2010, 6, 37-49.
119. Yang, S.Y. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov. Today, 2010, 15, 444-450.
120. Sun, H. Pharmacophore-based virtual screening. Curr. Med. Chem., 2008, 15, 1018-1024.
121. Krovat, E.M.; Langer, T. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J. Med. Chem., 2003, 46, 716-726.
122. Barelier, S.; Pons, J.; Gehring, K.; Lancelin, J.M.; Krimm, I. Ligand specificity in fragment-based drug design. J. Med. Chem., 2010, 53, 5256-5266.
123. Feyfant, E.; Cross, J.B.; Paris, K.; Tsao, D.H. Fragment-based drug design. Methods Mol. Biol., 2011, 685, 241-252.
124. Villar, H.O.; Hansen, M.R.; Kho, R. Substructural Analysis in Drug. Discovery. Curr. Comput. Aided Drug Des., 2007, 3, 59-67.
125. Machrouhi, F.; Ouhamou, N.; Laderoute, K.; Calaoagan, J.; Bukhtiyarova, M.; Ehrlich, P.J.; Klon, A.E. The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity. Bioorg. Med. Chem. Lett., 2010, 20, 6394-6399.
126. Raevsky, O.A. Physicochemical descriptors in property-based drug design. Mini. Rev. Med. Chem., 2004, 4, 1041-1052.
127. Shaikh, S.A.; Jain, T.; Sandhu, G.; Latha, N.; Jayaram, B. From drug target to leads--sketching a physicochemical pathway for lead molecule design in silico. Curr. Pharm. Des., 2007, 13, 3454-3470.
128. Wagener, M.; Lommerse, J.P. The quest for bioisosteric replacements. J. Chem. Inf. Model, 2006, 46, 677-685.
129. Ertl, P. In silico identification of bioisosteric functional groups. Curr. Opin. Drug Discov. Devel., 2007, 10, 281-288.
130. Bharatam, P.V.; Patel, D.S.; Iqbal, P. Pharmacophoric features of biguanide derivatives: an electronic and structural analysis. J. Med. Chem., 2005, 48, 7615-7622.
131. Guh, J.H.; Chang, W.L.; Yang, J.; Lee, S.L.; Wei, S.; Wang, D.; Kulp, S.K.; Chen, C.S. Development of novel adenosine monophosphate-activated protein kinase activators. J. Med. Chem., 2010, 53, 2552-2561.